세계의 난자 동결 및 배아 은행 시장 : 예측 - 서비스 유형별, 보존 방법별, 연령층별, 기술별, 용도별, 최종 사용자별, 지역별 분석(-2032년)

According to Stratistics MRC, the Global Egg Freezing and Embryo Banking Market is accounted for $5.37 billion in 2025 and is expected to reach $11.7 billion by 2032 growing at a CAGR of 11.8% during the forecast period. A woman's mature eggs are removed, frozen, and saved for later use in a fertility preservation procedure called egg freezing, also known as oocyte cryopreservation, which increases the likelihood of getting pregnant later in life. In order to preserve cell integrity, the procedure entails ovarian stimulation, egg removal, and quick freezing via vitrification. The process of creating, freezing, and storing embryos created by fertilizing eggs with sperm in a lab environment typically through in vitro fertilization (IVF) is known as embryo banking. These techniques, which give people or couples more reproductive flexibility and help, maintain fertility before ageing or medical treatments, are utilized for medical, social, or private reasons.

According to European Society of Human Reproduction and Embryology, more than 3 million ART cycles are performed annually across the world. Therefore, as the adoption of ART procedures expands so does the need for short term shortage.

Market Dynamics:

Driver:

Rising fertility concerns & medical reasons

The need for fertility preservation services has increased as a result of rising infertility rates brought on by stress, delayed family planning, and changes in lifestyle. As a preventative measure to preserve reproductive potential prior to age-related decline, many people choose to freeze their eggs. Before undertaking therapies that may affect fertility, patients with medical problems including cancer, endometriosis, or genetic diseases are also encouraged to preserve their eggs or embryos. Reproductive technology advancements have improved the accessibility and efficacy of these operations. When combined, these elements greatly accelerate the market's expansion and pace of adoption.

Restraint:

High costs & affordability issues

The procedures involve expensive medical treatments, medications, and storage fees. Many individuals, especially in low- and middle-income regions, cannot afford these services. Limited insurance coverage further increases the financial burden. As a result, potential users delay or avoid opting for fertility preservation. This restricts market growth and limits access to advanced reproductive options.

Opportunity:

Growing awareness & acceptance

People are more inclined to think about these possibilities sooner when they are well informed about reproductive health. As stigma is lessened by social acceptability, more people are becoming receptive to fertility preservation. The advantages are further emphasized by media attention and healthcare provider campaigns. Adoption is also aided by growing acceptance among employers who provide these perks. In general, market growth and client base expansion are being facilitated by awareness and acceptance.

Threat:

Infrastructure & access limitations

Modern fertility clinics and specialised storage facilities are scarce in many areas. The quality and scope of services are diminished by the scarcity of qualified medical personnel. Expansion is limited by the high startup costs for cryopreservation equipment and labs. Patients have trouble getting to healthcare facilities in isolated places. These obstacles restrict market penetration and impede adoption.

Covid-19 Impact:

The Covid 19 pandemic significantly disrupted the Egg Freezing and Embryo Banking Market, causing delays in fertility treatments due to clinic closures and travel restrictions. Elective procedures were postponed, leading to a temporary decline in service demand. Supply chain interruptions affected the availability of medical equipment and consumables. However, increased awareness of reproductive health, coupled with concerns over delayed pregnancies, boosted interest in fertility preservation post pandemic. Telemedicine adoption and digital consultations helped sustain patient engagement, while clinics adapted with enhanced safety protocols to resume operations efficiently.

The vitrification segment is expected to be the largest during the forecast period

The vitrification segment is expected to account for the largest market share during the forecast period by offering a rapid-freezing process that prevents ice crystal formation, ensuring higher cell survival rates. This advanced technique improves post-thaw viability of eggs and embryos, increasing the chances of successful fertilization and pregnancy. Its efficiency and reliability make it a preferred method among fertility clinics and patients. The shorter processing time also reduces operational costs and enhances clinical workflow. Growing awareness and adoption of vitrification technology are driving market growth globally.

The cryobanks segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the cryobanks segment is predicted to witness the highest growth rate due to advanced storage facilities that ensure the long-term preservation of reproductive materials. They offer secure and temperature-controlled environments, maintaining the viability and quality of eggs and embryos for extended periods. Cryobanks also expand accessibility by partnering with fertility clinics and offering convenient retrieval services. Technological advancements in cryopreservation methods within cryobanks improve survival rates after thawing, enhancing success rates of fertility treatments.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share is propelled by high fertility awareness, supportive employer sponsored benefits, and well developed healthcare infrastructure. The widespread trend of postponing parenthood for careers or education, combined with offers of egg freezing insurance by large corporations, also significantly accelerates adoption. Technological advantages include vitrification as the standard cryopreservation method, time-lapse imaging, AI driven embryo selection, and preimplantation genetic testing systems embedded in leading clinics. Employers and insurers play a key role by funding these services, reducing cost barriers, and widening access to fertility preservation.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR by rising infertility, increasing disposable incomes, and expanding urban female workforce participation in countries such as China, India, Japan, and South Korea. National government initiatives such as fertility subsidies in Tokyo and expanded IVF rebate programs in Australia-boost accessibility and consumer awareness. Innovation trends include ultra rapid vitrification, blockchain secured cry storage, scalability of embryo banks across borders, and AI based diagnostic tools tailored for local genetic screening and embryo assessment. Medical tourism also accelerates growth as regional clinics provide cost-effective, advanced fertility preservation services.

Key players in the market

Some of the key players in Egg Freezing and Embryo Banking Market include The Cooper Companies, Merck KGaA, Thermo Fisher Scientific Inc., Vitrolife AB, Ferring Pharmaceuticals, Kindbody, Virtus Health Limited, Monash IVF Group, Progyny, Inc., Shady Grove Fertility, Cryos International, California Cryobank, IVIRMA Global, FUJIFILM Irvine Scientific and Hamilton Thorne Ltd.

Key Developments:

In February 2025, Thermo Fisher Scientific launched the CorEvitas Systemic Lupus Erythematosus (SLE) Registry, a comprehensive real world clinical data platform. It aims to collect, analyze, and share longitudinal patient data to advance understanding, treatment development, and management strategies for autoimmune diseases.

In May 2024, Vitrolife AB acquired eFertility to integrate its eWitness tracking and eBase EMR systems, enabling secure, efficient, and standardized egg freezing and embryo banking workflows. This move strengthens Vitrolife's end to end IVF platform and advances its digital clinic management capabilities.

In May 2023, Thermo Fisher Scientific partnered with Pfizer to broaden access to lung and breast cancer testing, aiming to enhance early detection and personalized treatment. The collaboration focused on advanced diagnostic solutions, with no link to fertility preservation services.

Service Types Covered:

• Egg Freezing
• Embryo Banking
• Other Service Types

Preservation Methods Covered:

• Slow Freezing
• Vitrification

Age Groups Covered:

• <30 Years
• 30-39 Years
• >=40 Years
• Other Age Groups

Technologies Covered:

• In Vitro Fertilization (IVF)
• Intracytoplasmic Sperm Injection (ICSI)
• Other Technologies

Applications Covered:

• Medical Fertility Preservation
• Elective Fertility Preservation

End Users Covered:

• Fertility Clinics
• Hospitals
• Cryobanks
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Technology Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Egg Freezing and Embryo Banking Market, By Service Type

• 5.1 Introduction
• 5.2 Egg Freezing
• 5.3 Embryo Banking
• 5.4 Other Service Types

6 Global Egg Freezing and Embryo Banking Market, By Preservation Method

• 6.1 Introduction
• 6.2 Slow Freezing
• 6.3 Vitrification

7 Global Egg Freezing and Embryo Banking Market, By Age Group

• 7.1 Introduction
• 7.2 <30 Years
• 7.3 30-39 Years
• 7.4 >=40 Years
• 7.5 Other Age Groups

8 Global Egg Freezing and Embryo Banking Market, By Technology

• 8.1 Introduction
• 8.2 In Vitro Fertilization (IVF)
• 8.3 Intracytoplasmic Sperm Injection (ICSI)
• 8.4 Other Technologies

9 Global Egg Freezing and Embryo Banking Market, By Application

• 9.1 Introduction
• 9.2 Medical Fertility Preservation
• 9.3 Elective Fertility Preservation

10 Global Egg Freezing and Embryo Banking Market, By End User

• 10.1 Introduction
• 10.2 Fertility Clinics
• 10.3 Hospitals
• 10.4 Cryobanks
• 10.5 Other End Users

11 Global Egg Freezing and Embryo Banking Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 The Cooper Companies
• 13.2 Merck KGaA
• 13.3 Thermo Fisher Scientific Inc.
• 13.4 Vitrolife AB
• 13.5 Ferring Pharmaceuticals
• 13.6 Kindbody
• 13.7 Virtus Health Limited
• 13.8 Monash IVF Group
• 13.9 Progyny, Inc.
• 13.10 Shady Grove Fertility
• 13.11 Cryos International
• 13.12 California Cryobank
• 13.13 IVIRMA Global
• 13.14 FUJIFILM Irvine Scientific
• 13.15 Hamilton Thorne Ltd.